Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/179012
Title: | The role of CDK4/6 inhibitors in early breast cancer |
Author: | Gil Gil, Miguel Alba, Emilio Gavilá, Joaquín Haba Rodríguez, Juan de la Ciruelos, Eva Tolosa, Pablo Candini, Daniele Llombart Cussac, Antonio |
Keywords: | Càncer de mama Tractament adjuvant del càncer Breast cancer Adjuvant treatment of cancer |
Issue Date: | 1-Jul-2021 |
Publisher: | Elsevier BV |
Abstract: | The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.breast.2021.05.008 |
It is part of: | The Breast, 2021, vol.58, p. 160-169 |
URI: | http://hdl.handle.net/2445/179012 |
Related resource: | https://doi.org/10.1016/j.breast.2021.05.008 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PIIS0960977621003805.pdf | 328.25 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License